Sinil Pharmaceutical Co. Ltd (012790) — Cash Flow Quality Index
Sinil Pharmaceutical Co. Ltd (012790) has a Cash Flow Quality Index of 1.01x as of September 2025. Operating cash flow of ₩2.62 Billion exceeds net income of ₩2.61 Billion, indicating high earnings quality where cash backs reported profits. Explore 012790 long-term investments to assets to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Sinil Pharmaceutical Co. Ltd Cash Flow Quality Index (2014–2024)
Historical Cash Flow Quality Index for Sinil Pharmaceutical Co. Ltd across 11 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Sinil Pharmaceutical Co. Ltd tangible equity quality to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Sinil Pharmaceutical Co. Ltd (2014–2024)
Year-by-year earnings quality comparison for Sinil Pharmaceutical Co. Ltd. For live market cap and the full company financial profile, see market value of Sinil Pharmaceutical Co. Ltd.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 1.59x | ₩22.69 Billion | ₩14.30 Billion | ▲ +42.8% |
| 2023 | 1.11x | ₩15.15 Billion | ₩13.64 Billion | ▼ -1.3% |
| 2022 | 1.13x | ₩13.69 Billion | ₩12.16 Billion | ▼ -32.6% |
| 2021 | 1.67x | ₩11.16 Billion | ₩6.68 Billion | ▲ +14.0% |
| 2020 | 1.47x | ₩11.06 Billion | ₩7.54 Billion | ▼ -13.5% |
| 2019 | 1.70x | ₩12.31 Billion | ₩7.26 Billion | ▲ +5.4% |
| 2018 | 1.61x | ₩9.19 Billion | ₩5.71 Billion | ▲ +52.1% |
| 2017 | 1.06x | ₩8.67 Billion | ₩8.20 Billion | ▼ -12.2% |
| 2016 | 1.20x | ₩12.09 Billion | ₩10.04 Billion | ▲ +10.4% |
| 2015 | 1.09x | ₩9.56 Billion | ₩8.76 Billion | ▲ +19.1% |
| 2014 | 0.92x | ₩9.33 Billion | ₩10.18 Billion | — |